<DOC>
	<DOCNO>NCT01371981</DOCNO>
	<brief_summary>This randomized phase III trial study well bortezomib sorafenib tosylate work treat patient newly diagnose acute myeloid leukemia . Bortezomib sorafenib tosylate may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib sorafenib tosylate together combination chemotherapy may effective treatment acute myeloid leukemia .</brief_summary>
	<brief_title>Bortezomib Sorafenib Tosylate Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare event-free survival ( EFS ) overall survival ( OS ) patient de novo acute myeloid leukemia ( AML ) without high allelic ratio fms-like tyrosine kinase ( FLT3 ) /internal tandem duplication ( ITD ) + mutation randomize standard therapy versus bortezomib/standard combination therapy . II . To determine feasibility combine bortezomib standard chemotherapy patient de novo AML . III . To compare OS EFS high-risk patient treat intensive Induction II historical control AAML03P1 AAML0531 . IV . To determine feasibility administer sorafenib ( sorafenib tosylate ) standard chemotherapy one year maintenance phase patient de novo high allelic ratio FLT3/ITD+ AML . SECONDARY OBJECTIVES : I . To assess anti-leukemic activity sorafenib patient de novo high allelic ratio FLT3/ITD+ AML . II . To compare percentage patient convert positive minimal residual disease ( MRD ) negative MRD Intensive Induction II historical control AAML03P1 AAML0531 . III . To compare OS , disease-free survival ( DFS ) , cumulative incidence relapse , treatment-related mortality end Intensification I patient allocate best allogenic donor stem cell transplant ( SCT ) comparable patient AAML0531 receive allogenic donor SCT . IV . To compare OS , DFS , cumulative incidence relapse , treatment-related mortality , severe toxicity patient allocate matched family donor SCT AAML1031 AAML0531 . V. To assess health-related quality life ( HRQOL ) patient treat chemotherapy stem cell transplant ( SCT ) AML . VI . To evaluate bortezomib pharmacokinetics ( PK ) patient receive combination regimen . VII . To obtain sorafenib metabolite steady state pharmacokinetics pharmacokinetic-pharmacodynamic data subject FLT3/ITD receive sorafenib . VIII . To compare change shorten fraction/ejection fraction time patient treat without dexrazoxane . IX . To refine use minimal-residual disease ( MRD ) detection 4-color flow cytometry . X . To evaluate prognostic significance molecular MRD contribution risk identification multidimensional flow cytometry ( MDF ) -based MRD patient translocation amenable quantitative real time ( RT ) -polymerase chain reaction ( PCR ) ( e.g. , [ 8 ; 21 ] , inv [ 16 ] , [ 9 ; 11 ] , Wilms tumor 1 [ WT1 ] expression ) . XI . To determine leukemic involvement hematopoietic early progenitor cell role define response therapy . XII . To define leukemic stem cell population patient AML . XIII . To determine prevalence prognostic significance molecular abnormality WT1 , runt-related transcription factor ( RUNX ) 1 , mixed-lineage leukemia ( MLL ) -partial tandem duplication ( PTD ) , tet methylcytosine dioxygenase 2 ( TET2 ) , Cbl proto-oncogene , E3 ubiquitin protein ligase ( c-CBL ) , v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog ( KIT ) , novel AML-associated gene pediatric AML . XIV . Correlate expression cluster differentiation ( CD ) 74 antigen well proteasome beta 5-subunit ( PSMB5 ) gene expression mutation response bortezomib . XV . To evaluate change protein expression unfold protein response ( UPR ) patient AML . XVI . To determine expression level wild-type FLT3 , correlate outcome vitro sensitivity FLT3 inhibition . XVII . To collect biology specimen diagnosis , treatment time point , relapse future biology study XVIII . To create pediatric-specific algorithm predict occurrence grade 2-4 acute graft-versus-host disease ( GVHD ) prior clinical manifestation use combination pre-transplant clinical variable serum GVHD biomarker concentration first week SCT . OUTLINE : This dose-escalation study sorafenib tosylate . Patients randomize 1 2 treatment arm offer treatment 1 2 arm . ( Arms A B close new patient enrollment 02/04/2016 ) INDUCTION I : ARM A : Patients receive cytarabine intrathecally ( IT ) day 1 ADE chemotherapy comprise cytarabine intravenously ( IV ) 1-30 minute day 1-10 ; daunorubicin hydrochloride IV 1-15 minute day 1 , 3 , 5 ; etoposide IV 1-2 hour day 1-5 . ARM B : Patients receive cytarabine IT ADE chemotherapy Induction I , Arm A . Patients also receive bortezomib IV 3-5 second day 1 , 4 , 8 . ARM C ( high-risk [ HR ] FLT3/ITD+ disease ) : Patients receive cytarabine IT ADE chemotherapy Induction I , Arm A sorafenib tosylate orally ( PO ) day 11-28 . ARM D ( unknown FLT3/ITD status prior study enrollment ) : Patients receive cytarabine IT ADE chemotherapy Induction I , Arm A . If patient determine HR FLT3/ITD+ later end Induction I eligible participate Arm C. INDUCTION II : Patients without HR FLT3/ITD+ disease begin Induction II administration day 29 . ARM A ( low-risk [ LR ] patient ) : Patients receive cytarabine IT ADE chemotherapy Induction I Arm A . ARM A ( HR patient ) : Patients receive cytarabine IT day 1 MA chemotherapy comprise high-dose cytarabine IV 1-3 hour day 1-4 , mitoxantrone IV 15-30 minute day 3-6 . ARM B ( LR patient ) : Patients receive cytarabine IT , ADE chemotherapy , bortezomib Induction I Arm B . ARM B ( HR patient ) : Patients receive cytarabine IT MA chemotherapy Induction II , Arm A ( HR patient ) bortezomib IV day 1 , 4 , 8 . ARM C ( patient HR FLT3/ITD+ disease , cohort 3 ) : Patients receive cytarabine IT day 1 , cytarabine IV 1-30 minute day 1-8 , daunorubicin hydrochloride IV 1-15 minute day 1 , 3 , 5 , etoposide IV 1-2 hour day 1-5 , sorafenib tosylate PO day 9-36 . Patients achieve complete remission ( CR ) proceed Intensification I ( begin day 37 ) . Patients refractory disease protocol therapy . INTENSIFICATION I : ARM A : Patients receive cytarabine IT day 1 AE chemotherapy comprise high-dose cytarabine IV 1-3 hour , etoposide IV 1-2 hour day 1-5 . ARM B : Patients receive cytarabine IT AE chemotherapy Intensification II , Arm A , bortezomib IV day 1 , 4 , 8 . ARM C ( cohort 3 ) : Patients receive cytarabine IT AE chemotherapy Intensification II , Arm A , sorafenib tosylate PO daily day 6-28 . Patients achieve CR proceed Intensification II stem cell transplantation ( SCT ) begin day 34 . Patients refractory disease protocol therapy . INTENSIFICATION II : ARM A ( LR ) : Patients receive cytarabine IT day 1 MA chemotherapy Induction II , Arm A ( HR patient ) . ARM B ( LR ) : Patients receive cytarabine IT day 1 , MA chemotherapy Induction II , Arm A ( HR patient ) , bortezomib IV day 1 , 4 , 8 . ARMS A AND B ( HR donor SCT ) : Patients receive high-dose cytarabine IV 3 hour day 1 , 2 , 8 , 9 asparaginase intramuscularly ( IM ) day 2 9 . ARM C ( HR cohort 3 ) : Patients receive cytarabine IT day 1 , MA chemotherapy Induction II , Arm A ( HR patient ) , sorafenib tosylate PO day 7-34 . STEM CELL TRANSPLANTATION ( SCT ) ( HR patient match family [ MFD ] unrelated donor ) : CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV 30 minute daily day -5 -2 busulfan IV 2 hour 4 time daily day -5 -2 . TRANSPLANTATION : Patients undergo allogeneic SCT within 36 48 hour last dose busulfan . GVHD PROPHYLAXIS : Patients receive tacrolimus IV continuously PO begin day -2 continue day 98 ( match sibling donor ) day 180 ( taper ) ( related/unrelated donor cord blood ) methotrexate IV day 1 , 3 , 6 ( match sibling/cord blood donor ) day 1 , 3 , 6 , 11 ( related/unrelated donor ) . Patients unrelated donor also receive antithymocyte globulin IV 6-8 hour day -3 -1 . MAINTENANCE : Patients Arm C receive sorafenib tosylate PO start day 40-100 completion intensification II SCT one year . After completion study therapy , patient follow monthly 6 month , every 2 month 6 month , every 4 month 1 year , every 6 month 1 year , yearly thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sarcoma , Myeloid</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must newly diagnose de novo acute myelogenous leukemia Patients previously untreated primary AML meet customary criterion AML &gt; = 20 % bone marrow blast set 2008 World Health Organization ( WHO ) Myeloid Neoplasm Classification eligible Attempts obtain bone marrow either aspirate biopsy must make unless clinically prohibitive ; case clinically prohibitive , peripheral blood excess 20 % blast adequate flow cytometric cytogenetics/fluorescent situ hybridization ( FISH ) test feasible substitute marrow exam diagnosis Patients &lt; 20 % bone marrow blast eligible : A karyotypic abnormality characteristic de novo AML ( ( 8 ; 21 ) ( q22 ; q22 ) , inv ( 16 ) ( p13q22 ) ( 16 ; 16 ) ( p13 ; q22 ) 11q23 abnormalities The unequivocal presence megakaryoblasts , Biopsy proven isolate myeloid sarcoma ( myeloblastoma ; chloroma , include leukemia cutis ) Patients performance status eligible enrollment Prior therapy hydroxyurea , alltrans retinoic acid ( ATRA ) , corticosteroid ( route ) , IT cytarabine give diagnosis allow ; hydroxyurea ATRA must discontinue prior initiation protocol therapy ; patient previously receive chemotherapy , radiation therapy antileukemic therapy eligible protocol Patients follow constitutional condition eligible : Fanconi anemia Shwachman syndrome Any know bone marrow failure syndrome Patients constitutional trisomy 21 constitutional mosaicism trisomy 21 Note : enrollment may occur pending result clinically indicated study exclude condition Patients follow oncologic diagnosis eligible : Any concurrent malignancy Juvenile myelomonocytic leukemia ( JMML ) Philadelphia chromosome positive AML Biphenotypic bilineal acute leukemia Acute promyelocytic leukemia Acute myeloid leukemia arise myelodysplasia Therapyrelated myeloid neoplasms Note : enrollment may occur pending result clinically indicated study exclude condition Pregnancy breast feed Female patient pregnant ineligible Lactating female eligible unless agree breastfeed infant Female patient childbearing potential eligible unless negative pregnancy test result obtain Sexually active patient reproductive potential eligible unless agree use effective contraceptive method duration study participation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>